Many bears on Wall Street say that biotech stocks are overvalued, but many trade in line with historical valuations. In a new research report, Cowen highlights upcoming catalysts that could send some of the…
La Jolla Pharmaceutical shares surged after the micro-cap biotech said late Monday that its study for a chronic kidney disease treatment showed a statistically significant improvement.
Based on figures from the Gallup-Healthways Well-Being Index, 24/7 Wall St. reviewed the 10 states with the highest obesity rates. Mississippi was the fattest state in America, with 35.4% of its residents considered obese.
ThinkstockMore than 40% of health insurance plan customers were dissatisfied with their plan’s coverage, according to the latest data from J.D. Power’s 2014 Member Health Plan Study. Overall member satisfaction based on the survey…
In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the Cowen 2014 Healthcare Conference by large cap pharmaceutical companies concerning upcoming events and drugs.
ThinkstockThe latter part of the week was difficult for the biotech and specialty pharmaceutical sector. Unsettling news out of Washington, D.C., on potential changes in the taxation of the sector let the selling roll.…
ThinkstockWhat would appear to be an obscure initial public offering from LVB Acquisition Inc. is much more important than it might seem. This is actually the old medical devices company Biomet, and its name…
The biotech and specialty pharmaceutical groups got hit hard Thursday for a variety of reasons. The largest of which the analysts at Jefferies believe, is commentary within Washington's new budget proposal regarding tax inversion…
ThinkstockDendreon Corp. (NASDAQ: DNDN) remains a company in trouble. The post-earnings jump looked promising and investors probably took some comfort when shares popped from $2.88 up to $3.31. Unfortunately, that did not last and…
Peregrine Pharmaceuticals may be on the verge of something big with its anticancer drugs. The shares soared almost 50% on Wednesday. It is working on developing drugs that can train the body's immune system…
Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to outperform for the balance of 2014. Here are some of the top health care…
Shares of Dendreon moved higher Monday after the biotech company said it will start to market Provenge, its prostate-cancer drug, in Europe this year. Its fourth-quarter loss was smaller than expected as well.
ThinkstockWith the top stocks in the market exploding in price due to the recent rally, we wanted to scan across our research universe for some lower priced names that could have significant upside. As…
Compugen is raising close to $60 million in a secondary offering, but at a punishing price to any new shareholders who bought into this week's strength.
Merrill Lynch issued a note on Aegerion Pharmaceuticals in the wake of its earnings report that both maintained a Buy rating and maintained its $102 price target. This target implies about 70% upside.